RushMab™是百英生物近期推出的一项高通量抗体服务套餐。主要目的在提供成本效益高,节省时间,性价比高的解决方案,以满足客户对抗体表达的小规模紧急需求。RushMab™套餐生产周期最短8天,并具有超过5000个样本的大规模生产能力。
前往百英官网获取更多信息 >>
RushMab™ - Super (24/96-well plate)
RushMab™ - Super , is a breakthrough package in Biointron's newly launched service promotions. This high-efficiency service provides 1 ml supernatant along with expression plasmids as deliverables. The production can be completed in as few as 8 days , with titer detection as the standard QC option.
-
Production Timeline: 8 Days
-
Deliverables: 1 ml supernatant, Expression plasmids
-
QC: Titer detection
RushMab™ - Mini
RushMab™ - Mini , focus on rapid turnaround and quality, this package provides you with no less than 100 ug of purified antibody and expression plasmids within 10 days . As with all our services, quality assurance is paramount. The default QC for RushMab™ - Mini includes detailed SDS-PAGE and SEC-HPLC analyses to ensure you receive premium, reliable products.
-
Production Timeline: 10 Days
-
Deliverables: ≥100 ug purified antibody, Expression plasmids
-
QC: SDS-PAGE, SEC-HPLC
RushMab™ - Standard
RushMab™ - Standard , an integral part of our newly launched Small-Scale Packages, specifically designed for speed and precision. This package offers you more than 1 mg of purified antibody and accompanying expression plasmids, with a complete production timeline of 10 days . We prioritize quality assurance, with the default QC offering including SDS-PAGE and SEC-HPLC analyses, and an endotoxin level guaranteed to be less than 1 EU/mg .
-
Production Timeline: 10 Days
-
Deliverables: ≥1 mg purified antibody, Expression plasmids
-
QC: SDS-PAGE, SEC-HPLC
公司介绍
Company Introduction
百英生物(Biointron)成立于2012年,是一家专注于抗体表达和抗体发现与优化CRO服务的国家高新技术企业、上海市科技小巨人培育企业、上海市专精特新企业。目前公司在上海周浦、江苏泰州设有研发和生产中心,在美国设有商务中心,以“抗体发现的加速器”为使命,致力成为全球抗体产业杰出的赋能者,提供一站式抗体发现服务。
百英生物在抗体表达服务领域处于行业领先地位,在基因、细胞和工艺层面建立了技术优势,并实现了标准化、自动化和信息化,服务质量获得了跨国制药企业的认可,服务了境内外超过20个国家和地区的近1,500家医药企业客户。
公司依托优异的抗体表达能力,为抗体发现和优化业务赋能,打造抗体发现一站式服务。陆续推出了纳米抗体开发服务、杂交瘤抗体测序服务、抗体人源化服务、抗体亲和力成熟服务和单B细胞抗体筛选服务等抗体发现与优化业务。
此外,公司取得ECACC的CHO-K1的全球范围商业化再授权许可,可在全球范围进行商业化再授权,驯化后的CHOK1BN细胞株已完成国内与国际第三方检测机构的检定,并已完成美国FDA的DMF备案,符合国际多中心申报要求,已有客户项目进入国际多中心临床阶段。
如果您需要了解更多信息,请访问我们的官方网站www.biointron.com或联系[email protected]